Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Hernando-Calvo

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Cancer Discovery|June 3, 2023
Patient-Centric Approaches for Phase I Combination Trials Come on StageAlberto Hernando-Calvo, Elena Garralda
Breast Cancer Research and Treatment|October 8, 2021
Novel classes of immunotherapy for breast cancerAlberto Hernando-Calvo, David W Cescon, Philippe L Bedard
Cancer Treatment Reviews|May 19, 2024
Agnostic drug development revisitedAlberto Hernando-Calvo, Alice Rossi, Maria Vieito, et al.
Cancer Treatment Reviews|May 31, 2024
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapiesPablo Jiménez-Labaig, Antonio Rullan, Alberto Hernando-Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2022
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trialsAbdulazeez Salawu, Alberto Hernando-Calvo, Rachel Y Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
A risk stratification model for toxicities in phase 1 immunotherapy trialsAlberto Hernando-Calvo, Abdulazeez Salawu, Rachel Y Chen, et al.
Cancer Treatment Reviews|October 9, 2022
Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias"Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berché, et al.
Oncotarget|June 17, 2025
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatmentAlberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, et al.
Frontiers in Immunology|November 7, 2025
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategiesGreta Catani, Daniel Morchón-Araujo, Oriol Mirallas, et al.
Cancer Treatment Reviews|May 2, 2024
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectivesPablo Jiménez-Labaig, Antonio Rullan, Irene Braña, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Cancer Discovery|June 3, 2023
Patient-Centric Approaches for Phase I Combination Trials Come on StageAlberto Hernando-Calvo, Elena Garralda
Breast Cancer Research and Treatment|October 8, 2021
Novel classes of immunotherapy for breast cancerAlberto Hernando-Calvo, David W Cescon, Philippe L Bedard
Cancer Treatment Reviews|May 19, 2024
Agnostic drug development revisitedAlberto Hernando-Calvo, Alice Rossi, Maria Vieito, et al.
Cancer Treatment Reviews|May 31, 2024
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapiesPablo Jiménez-Labaig, Antonio Rullan, Alberto Hernando-Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2022
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trialsAbdulazeez Salawu, Alberto Hernando-Calvo, Rachel Y Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
A risk stratification model for toxicities in phase 1 immunotherapy trialsAlberto Hernando-Calvo, Abdulazeez Salawu, Rachel Y Chen, et al.
Cancer Treatment Reviews|October 9, 2022
Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias"Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berché, et al.
Oncotarget|June 17, 2025
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatmentAlberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, et al.
Frontiers in Immunology|November 7, 2025
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategiesGreta Catani, Daniel Morchón-Araujo, Oriol Mirallas, et al.
Cancer Treatment Reviews|May 2, 2024
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectivesPablo Jiménez-Labaig, Antonio Rullan, Irene Braña, et al.
Pageof 4